June 23, 2020 / 5:11 AM / 20 days ago

BRIEF-Targovax Announces Collaborative Agreement With Merck & Co

June 23 (Reuters) - Targovax ASA:

* TARGOVAX ANNOUNCES COLLABORATION TO EVALUATE ONCOS-102 IN COMBINATION WITH KEYTRUDA[®] IN MESOTHELIOMA

* COLLABORATIVE AGREEMENT WITH MERCK & CO., INC., KENILWORTH, NJ, USA

* AIM IS TO START ENROLLING PATIENTS INTO TRIAL WITHIN TWELVE MONTHS

* MULTIPLE CENTERS IN BOTH USA AND EU WILL BE PARTICIPATING

* TO EVALUATE COMBINATION OF ONCOS-102, KEYTRUDA MSD’S ANTI-PD-1 THERAPY, AND STANDARD OF CARE CHEMOTHERAPY IN MALIGNANT PLEURAL MESOTHELIOMA

* TRIAL WILL BE A RANDOMIZED PHASE II OF UP TO 100 PATIENTS COMPARING THIS INVESTIGATIONAL TRIPLE COMBINATION AGAINST KEYTRUDA AND SOC Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below